Also published as: Mi Ok Kim, S Y Kim, Chul-Hong Kim, Do Hyung Kim, Sydney Y Kim, Sung Young Kim, Chongtae Kim, Myung-Sunny Kim, Hyeong-Rok Kim, Miri Kim, Dong Il Kim, Hyeon-Ah Kim, Esther Kim, Ok-Hwa Kim, Juyong B Kim, Joong-Seok Kim, Jong Woo Kim, Saerom Kim, Wondong Kim, Seong-Hyun Kim, Misung Kim, Dong-Ik Kim, Minsuk Kim, Ohn Soon Kim, Sung Han Kim, Sung Tae Kim, Richard Kim, Albert H Kim, Ju Deok Kim, Chong Ae Kim, Hyun-Ji Kim, Yong Kyung Kim, Jisun Kim, Haein Kim, Jeonghan Kim, Hee Jin Kim, Minjae Kim, Hyun Kim, Kyoung Oh Kim, Jiyea Kim, Jun Hoe Kim, Joon Kim, Sunghwan Kim, Bo-Rahm Kim, Namkyoung Kim, Hee Jeong Kim, Kangjoon Kim, Younghoon Kim, Jae Geun Kim, Min Kyeong Kim, Hyeong-Taek Kim, Kevin K Kim, Soeun Kim, Sungup Kim, Jeong Su Kim, Gwang Sik Kim, Anthony S Kim, Ok Jin Kim, Jeongseop Kim, Bo-Eun Kim, Suk-Kyung Kim, Sang Soo Kim, Hae Won Kim, Taeil Kim, Joonyoung R Kim, Kyung-Hee Kim, Hyeyoon Kim, Hyojin Kim, Yangseok Kim, Jong Ho Kim, Chunki Kim, Seokjoong Kim, Mi Ra Kim, Young-Dae Kim, Young Mi Kim, Na-Kuang Kim, Yoon Sook Kim, Byoung Jae Kim, Daham Kim, Mijung Kim, Yu Kyeong Kim, Yong-Lim Kim, Jin-Chul Kim, Chan Wook Kim, Hyeong-Jin Kim, Sang Hyuk Kim, Gibae Kim, Sang Ryong Kim, Jieun Kim, Jongchan Kim, Joseph C Kim, Jun Pyo Kim, Brandon J Kim, Jun-Sik Kim, Ji Eun Kim, Jung-In Kim, Chan-Wha Kim, B-Y Kim, B T Kim, Dahee Kim, Taek-Yeong Kim, Hyunjoon Kim, Young-Saeng Kim, Hyeon Jeong Kim, Hyemin Kim, Shin Kim, Y S Kim, Dan Say Kim, Ji-Dam Kim, Paul T Kim, Kyoung Hoon Kim, Ye-Ri Kim, Hee-Jin Kim, Jason Kim, Youngsin Kim, Hyuk Soon Kim, Seung-Ki Kim, Moon Suk Kim, Young Ju Kim, Yunwoo Kim, J Y Kim, Lia Kim, Soo-Hyun Kim, Byung Jin Kim, You-Sun Kim, Youngsoo Kim, Yunkyung Kim, Meelim Kim, Kye-Seong Kim, Minseon Kim, Hye-Jin Kim, Il-Man Kim, Dong Ha Kim, Soo Yoon Kim, Stuart K Kim, Soo Hyun Kim, Il-Chan Kim, Mi-Na Kim, Yeong-Sang Kim, Eunmi Kim, Taewan Kim, Yun Seok Kim, Kyung Hee Kim, M Kim, Hyun Eun Kim, Eunkyeong Kim, Soee Kim, Young-Im Kim, So-Hee Kim, Hyeong Hoe Kim, Hee Young Kim, Eungseok Kim, Sungyun Kim, Tae-You Kim, Jong-Yeon Kim, Tae Hoon Kim, Sungrae Kim, Eun-Jin Kim, Heejin Kim, Tae Jin Kim, Ju Young Kim, Un-Kyung Kim, Jin Woo Kim, Gu-Hwan Kim, Young-Mi Kim, Dae-Kyum Kim, Tae-Min Kim, Seon-Kyu Kim, Hana Kim, Hye Ran Kim, Yuli Kim, Jung Ho Kim, Edwin H Kim, Grace Kim, Jongho Kim, Soung Jung Kim, Jinsup Kim, Dong-Kyu Kim, Su-Hyeong Kim, Kee-Tae Kim, Nam-Ho Kim, Jin Gyeom Kim, Mi Young Kim, Hyun-Sic Kim, Kyung-Sup Kim, Hyeonwoo Kim, Dong Gwang Kim, Jong-Youn Kim, Doo Yeon Kim, Jong-Il Kim, Soo Whan Kim, Kwang-Eun Kim, Jong-Won Kim, Eung-Gook Kim, Jaehoon Kim, Hyoung Kyu Kim, Hark Kyun Kim, Jonggeol J Kim, Sang Eun Kim, Jeong Kyu Kim, Eun Ji Kim, Youngmi Kim, William Kim, Jiho Kim, Dae In Kim, Dennis Y Kim, Sunghun Kim, Nari Kim, Doyeon Kim, Sang-Min Kim, Myeong-Kyu Kim, Youngsook Kim, Angela H Kim, Hye-Jung Kim, Hyung-Suk Kim, Hang-Rai Kim, Hyoun-Ah Kim, Sung-Wan Kim, Myung-Sun Kim, Mi Kyung Kim, Eun Young Kim, Jinhee Kim, Hyung-Gu Kim, Woo Sik Kim, In Suk Kim, Sung Eun Kim, Yekaterina Kim, Juyoung Kim, Hong-Hee Kim, Hye-Sung Kim, Ji Hyun Kim, Kyung Mee Kim, Sunghak Kim, Dong-Hoon Kim, Yong-Wan Kim, Seul Young Kim, Myoung Ok Kim, Jong-Seok Kim, H Kim, Minsik Kim, Sang-Young Kim, June-Bum Kim, Dong Hyun Kim, Jihoon Kim, Jaegil Kim, Tae Wan Kim, Seonggon Kim, Seongho Kim, Dong Wook Kim, Jun-Hyung Kim, Don-Kyu Kim, Kyung An Kim, Jun Suk Kim, Jung-Lye Kim, Dongkyun Kim, Sung Kyun Kim, Yerin Kim, Seung Woo Kim, Jun W Kim, Eunae Kim, Won Tae Kim, Kyung-Sub Kim, Kang Ho Kim, Chul Hwan Kim, Yong Sig Kim, Hong-Kyu Kim, Go Woon Kim, Peter K Kim, Taeeun Kim, Eunhyun Kim, Min-Sik Kim, Hyejin Kim, Chang-Yub Kim, Kyunggon Kim, Sinai Kim, Jiyeon Kim, Chong Kook Kim, Minkyung Kim, Cecilia E Kim, Jae Seon Kim, Yeon-Jeong Kim, Ha-Neui Kim, Kwan Hyun Kim, Jongwan Kim, Young Hun Kim, Nam Hee Kim, Jong Yeol Kim, Ji-Hoon Kim, Ki Tae Kim, Young-Bum Kim, Hyojung Kim, Woonhee Kim, Minjeong Kim, Sae Hun Kim, Sohee Kim, Jong-Joo Kim, Sangsoo Kim, Yong-Woon Kim, Geun-Young Kim, Jae-Jun Kim, K-K Kim, Jung-Taek Kim, Jeeyoung Kim, Min-Sun Kim, Kwang Pyo Kim, Ngoc-Thanh Kim, Chan-Duck Kim, Hyeon Ho Kim, Soo-Youl Kim, Young Tae Kim, Shi-Mun Kim, Kwang-Pyo Kim, Hee Jong Kim, Minah Kim, Taehyoun Kim, Yonghwan Kim, Won Dong Kim, Su-Jeong Kim, Eunha Kim, Min-Hyun Kim, Kyeongjin Kim, Min Kim, Sung Won Kim, Se-Wha Kim, Myeoung Su Kim, Eonmi Kim, In-Hoo Kim, Nan Young Kim, Myeong Ok Kim, Wootae Kim, In Kyoung Kim, Leen Kim, Doo Yeong Kim, Do-Hyung Kim, Dong-Hyeok Kim, Joonseok Kim, So Yeon Kim, Kwangho Kim, Seok Won Kim, Bo Ri Kim, TaeHyung Kim, Woo Jin Kim, Misun Kim, Serim Kim, Junesun Kim, Young Ree Kim, Choel Kim, Jae Hun Kim, Jin-Soo Kim, Jimi Kim, You-Jin Kim, Goun Kim, Goo-Young Kim, Jong Han Kim, Bongjun Kim, Sun-Joong Kim, Young Ho Kim, Kyung Sup Kim, Young Jin Kim, Scott Y H Kim, Chang Seong Kim, Ryung S Kim, Kellan Kim, Han Gyung Kim, Jae Hoon Kim, Jung-Ha Kim, Jaeyeon Kim, Hyung-Mi Kim, Hye-Young H Kim, Ho Shik Kim, Hwijin Kim, Kyungtae Kim, Ki Kwon Kim, Yongae Kim, Jaemi Kim, Hyun-ju Kim, Tai Kyoung Kim, Se Hyun Kim, Hyeseon Kim, Jin Cheon Kim, Hyung-Ryong Kim, Carla F Kim, Hyunki Kim, Yong-Sik Kim, Joonki Kim, Hyung-Sik Kim, Ah-Ram Kim, Deok Ryong Kim, Hyunyoung Kim, Jung Ki Kim, Yongkang Kim, Brian S Kim, Minchul Kim, Kahye Kim, Jae-Ryong Kim, Heegoo Kim, In Joo Kim, Sung-Jo Kim, Sang Chan Kim, Kyuho Kim, Sunkyu Kim, Beom-Jun Kim, Wanil Kim, Hei Sung Kim, Woojin Scott Kim, Won Jeoung Kim, Jungwoo Kim, Yejin Kim, Kyu-Kwang Kim, Yong-Soo Kim, Yong-Ou Kim, M J Kim, Yoonjung Kim, Chul Hoon Kim, Hyun-Jung Kim, Jae Hyoung Kim, Hyun Joon Kim, Hyun-Jin Kim, Ok-Kyung Kim, Kyungsook Kim, Kyungwon Kim, Jin Kim, Suji Kim, Ok-Hyeon Kim, Jung-Woong Kim, Seoyeon Kim, Kyeong-Min Kim, Sang-Hoon Kim, Hyun Gi Kim, Jooho Kim, Myung-Jin Kim, Eun-Jung Kim, Sangchul Kim, Joori Kim, Min Jung Kim, Jeeho Kim, Jihye Kim, Mi-Young Kim, Choon Ok Kim, Na Yeon Kim, Seong-Ik Kim, Jisu Kim, Dong-Hyun Kim, Myungsuk Kim, Eui Hyun Kim, Won-Tae Kim, Sung Soo Kim, Eun Kim, Hyung Min Kim, Jihyun Kim, Kwang Dong Kim, Suhyun Kim, Elizabeth H Kim, Sang-Gun Kim, Han-Kyul Kim, Yong Deuk Kim, Jong-Seo Kim, Young-Ho Kim, Yoo Ri Kim, Eiru Kim, Ji Yeon Kim, Ki Hyun Kim, Tae Hun Kim, Ae-Jung Kim, Eosu Kim, Cheorl-Ho Kim, TaeYeong Kim, Yeon-Hee Kim, Jae Suk Kim, Richard B Kim, Young-Jin Kim, Deokhoon Kim, Eung Yeop Kim, K-S Kim, Daeseung Kim, Ji Hun Kim, Mi-Sung Kim, Young Woo Kim, Taehyeung Kim, Meesun Kim, Sook Young Kim, Jaewon Kim, In Su Kim, Heebal Kim, Seungsoo Kim, Bong-Jo Kim, Seon Hwa Kim, Luke Y Kim, Jae-Ick Kim, Hwajung Kim, Jisook Kim, Jeffrey J Kim, Kyung Do Kim, Jungeun Kim, Youbin Kim, Jeong-Min Kim, Seokhwi Kim, D-W Kim, Su-Yeon Kim, Jung Hee Kim, Wook Kim, Jun-Mo Kim, Seon Hee Kim, Hong-Gi Kim, Hyun-Young Kim, Young Hwa Kim, Hyung Bum Kim, Dae-Soo Kim, Gitae Kim, Hyun-Yi Kim, Sejoong Kim, Hyungsoo Kim, Hyunmi Kim, June Soo Kim, Gyudong Kim, Rokki Kim, Yong Sook Kim, Young-Il Kim, Jinsu Kim, Woo-Yang Kim, Eunjoon Kim, Woo Kim, Jang-Hee Kim, Won Seok Kim, Seung Tea Kim, Tae Il Kim, Sung-Hou Kim, H S Kim, Suhyung Kim, Jong-Ho Kim, Jong Heon Kim, So Young Kim, Yeonsoo Kim, Jiha Kim, Young-Youn Kim, Hye Yun Kim, Arie Kim, Sun-Hee Kim, Min Wook Kim, Hyung-Jun Kim, Jae Hyun Kim, Sewoon Kim, Jin Seok Kim, Eunju Kim, Yun Hye Kim, Sun-Hong Kim, Soyeong Kim, Sowon Kim, Young Sik Kim, Mi-Hyun Kim, Byung-Gyu Kim, JongKyong Kim, Jin Young Kim, So Ree Kim, Aram Kim, Youn-Jung Kim, Joung Sug Kim, Hail Kim, Eui Jin Kim, Cheol-Su Kim, Ngoc Thanh Kim, Seong-Seop Kim, Ji-Man Kim, Ju-Kon Kim, Soo Wan Kim, Woong-Ki Kim, Ju-Wan Kim, Sunggun Kim, Sun Woong Kim, Jin Kyong Kim, Hoguen Kim, Hyungkuen Kim, Ji Hye Kim, Myoung Hee Kim, Min Ju Kim, Deok-Ho Kim, Woo-Shik Kim, Mina K Kim, Kiyoung Kim, Paul H Kim, Eun-Kyung Kim, Da-Sol Kim, Yeaseul Kim, In Ja Kim, Beomsu Kim, Byungwook Kim, Sun Yeou Kim, Jongmyung Kim, Helen Kim, Sungyeon Kim, Dae-Eun Kim, Jayoun Kim, Jung Dae Kim, Joseph Han Sol Kim, E-S Kim, Boo-Young Kim, Sung-Mi Kim, Dongwoo Kim, Seul-Ki Kim, Hye Jin Kim, Soo Young Kim, Sukjun Kim, Dong Joon Kim, Hyo Jung Kim, Yeseul Kim, Yong Sik Kim, Nam-Eun Kim, Sang-Tae Kim, Hong Sug Kim, Youngjoo Kim, Sun-Gyun Kim, Min-Gon Kim, Young-Woo Kim, Myungshin Kim, Tae Hoen Kim, Soon Hee Kim, Won Kim, Chanhee Kim, Jung Oh Kim, Hyun-Kyong Kim, Jeffrey Kim, Yeonhwa Kim, Yeon Ju Kim, Duck-Hee Kim, Seohyeon Kim, Soon Sun Kim, Jae Bum Kim, Yeul Hong Kim, Juhyun Kim, Chang-Gu Kim, Gwangil Kim, Alison J Kim, Hwa-Jung Kim, Youngeun Kim, Cheol-Hee Kim, NamHee Kim, Byung-Chul Kim, Cecilia Kim, S Kim, Tae-Gyu Kim, Kwan-Suk Kim, Jee Ah Kim, Kyoungtae Kim, Seong Jun Kim, Mi Jeong Kim, Myoung Sook Kim, Chu-Young Kim, Minsu Kim, Seong-Tae Kim, Donghyeon Kim, Sunoh Kim, Yu-Jin Kim, Yul-Ho Kim, Eric Kim, Jae-Young Kim, Jin Hee Kim, Tae Min Kim, Yeji Kim, Yo-Han Kim, Kyong-Tai Kim, Dae-Kyeong Kim, June Hee Kim, Tae Hyun Kim, Leo A Kim, Young S Kim, Min Bum Kim, Min Seo Kim, Seong-Jin Kim, Young-Chul Kim, Jinkyeong Kim, SooHyeon Kim, Kwangwoo Kim, Dong-Hee Kim, Sang Wun Kim, Won J Kim, Seung Won Kim, Ji-Yul Kim, Moo-Yeon Kim, Do Yeon Kim, Jun Seok Kim, Su-Jin Kim, Jewoo Kim, A Ram Kim, Hyung Hoi Kim, Song-Rae Kim, Hye-Ran Kim, Yoongeum Kim, Jeong-Han Kim, Jinsoo Kim, Steve Kim, Taeyoung Kim, Hwi Seung Kim, Hye Ree Kim, Hyeong-Geug Kim, Yu Mi Kim, J H Kim, Suk Jae Kim, Sung-Hee Kim, Na-Young Kim, Minji Kim, Jongkyu Kim, Jae-Yoon Kim, Hyunjin Kim, Helen B Kim, Dong-Yi Kim, Ji-Yun Kim, Sung Woo Kim, Ha-Jung Kim, Yongmin Kim, Han Young Kim, Hyun-Soo Kim, Hyunju Kim, Jin Man Kim, Young Nam Kim, Hye Young Kim, Sung Yeol Kim, Jong-Oh Kim, Y-D Kim, Jong-Hyun Kim, Jenny H Kim, Youngchang Kim, Okhwa Kim, Y A Kim, Won Kyung Kim, Dongjoon Kim, Myung Jin Kim, Hannah Kim, Ick Young Kim, Hyunsoo Kim, Sungjoo Kim, Seonhee Kim, Y-M Kim, Sun Hee Kim, Jung Sun Kim, Ji Young Kim, Sung-Eun Kim, Wun-Jae Kim, Hee Nam Kim, Vladimir Kim, Donghee Kim, Sang Jin Kim, Won Ho Kim, Byeong-Won Kim, Hyung-Goo Kim, J Julie Kim, Jiwon Kim, Eun-Joo Kim, Hyun Soo Kim, Tae-Hyoung Kim, Anna Kim, Gahyun Kim, Jong Hwan Kim, Borahm Kim, Caroline Kim, Andrea J Kim, Yong-Hoon Kim, Jisup Kim, Yong Kyun Kim, Young-Eun Kim, Angela Kim, Tae-Eun Kim, Ji Won Kim, Sang Geon Kim, Young-Cho Kim, Bo Young Kim, Minsoon Kim, Paul Kim, Jeongseon Kim, Tae-Mi Kim, Oc-Hee Kim, Da-Hyun Kim, Jong Geun Kim, Woo Kyung Kim, Jae-Yong Kim, Jaeuk U Kim, Kye Hyun Kim, Dae-Jin Kim, Jun Chul Kim, Dae Keun Kim, You Sun Kim, Heung-Joong Kim, Angela S Kim, Ji-Young Kim, So-Woon Kim, Dayoung Kim, Sangwoo Kim, Eric Eunshik Kim, Yeeun Kim, Jeewoo Kim, Sungmin Kim, Hyun Sil Kim, Young Hee Kim, Kyunga Kim, Donghyun Kim, Sung-Kyu Kim, Hanah Kim, Do-Kyun Kim, Jonggeol Jeffrey Kim, Min Soo Kim, Ju Han Kim, Hyung Yoon Kim, Youngchul Kim, Minhee Kim, Byung-Taek Kim, Sung-Bae Kim, Suk-Jeong Kim, Min-A Kim, Jae T Kim, Dong-Seok Kim, Min-Seon Kim, Hyoun Ju Kim, JungMin Kim, Kwonseop Kim, Kyong Min Kim, Jae-Jung Kim, Howard H Kim, Min-Seo Kim, Minjoo Kim, Sujung Kim, Woo-Kyun Kim, Yongjae Kim, Jong-Kyu Kim, Dong-il Kim, Jeri Kim, Seol-A Kim, Soriul Kim, Kil-Nam Kim, Soo-Rim Kim, Yun-Jin Kim, Yeonjung Kim, Su Jin Kim, Kyung Woo Kim, Yeon-Jung Kim, Jeong Hee Kim, Youn Shic Kim, Dong-Eun Kim, So-Yeon Kim, C H Kim, Sung-Hoon Kim, Namphil Kim, Kyung-Chang Kim, Chan-Hee Kim, Sun Hye Kim, Seulhee Kim, Joonyoung Kim, Gunhee Kim, Joungmok Kim, Seung-Whan Kim, Sang-Woo Kim, Seongmi Kim, Daegyeom Kim, Da Sol Kim, Ellen Kim, Young Rae Kim, Hee-Sun Kim, Seung Jun Kim, Kyungjin Kim, Youn-Kyung Kim, Sunghoon Kim, Jung-Hyun Kim, Young Eun Kim, Ho-Sook Kim, Hyun Ju Kim, Gyeonghun Kim, Baek Kim, Soon-Hee Kim, David E Kim, Joong Sun Kim, Hoon Seok Kim, Yunjung Kim, Keun You Kim, Min Cheol Kim, Gye Lim Kim, Dakyung Kim, Jong Won Kim, Hoon Kim, Seung-Jin Kim, Myeong Ji Kim, NamDoo Kim, Jinho Kim, Hyo Jong Kim, Young-Woong Kim, Un Gi Kim, Tae-Hyun Kim, Kee-Pyo Kim, Oh Yoen Kim, Juyeong Kim, Jun Hee Kim, Chae-Hyun Kim, Leo Kim, Eun Ho Kim, Haeryoung Kim, Seong Kim, Jessica Kim, Jin Won Kim, Hyun Sook Kim, Kyeongmi Kim, Rosalind Kim, Sujin Kim, E Kim, Nam-Hyung Kim, Sin Gon Kim, Seohyun Kim, Boram Kim, Kyeong Jin Kim, Gi Beom Kim, Jason K Kim, Hyung-Seok Kim, Dae Hyun Kim, Jina Kim, Ji-Won Kim, Eui-Soon Kim, Minkyeong Kim, M V Kim, Yumi Kim, Sunyoung Kim, Maya Kim, Mijeong Kim, Hyunbae Kim, Esl Kim, Su Kang Kim, Ju-Ryoung Kim, Bomi Kim, Kyung Han Kim, Seoyoung Kim, Ji-Eun Kim, Yoojin Kim, Minju Kim, Tae-Woon Kim, Jae Gon Kim, Hyeong Su Kim, Choon-Song Kim, Kye Hun Kim, Hyesung Kim, Yeon-Ki Kim, Jaeyoon Kim, Hyeung-Rak Kim, Kook Hwan Kim, Sung Hyun Kim, Sol Kim, Hyunwoo Kim, Min Joo Kim, Dong-Wook Kim, Young Sam Kim, Hye-Yeon Kim, Yun Joong Kim, Ki Woong Kim, Jungsu Kim, Misu Kim, Seung Chul Kim, Mi-Yeon Kim, Hyo-Soo Kim, Won Kon Kim, Sangmi Kim, Jong Deog Kim, Yun Gi Kim, Seon-Young Kim, Il-Sup Kim, Byung Guk Kim, Susy Kim, Youngwoo Kim, Min-Young Kim, Jae-Min Kim, Yong Sung Kim, Young-Won Kim, Jung H Kim, Eun Hee Kim, Yong Kwan Kim, Haelee Kim, Daesik Kim, Gukhan Kim, Hyungjun Kim, Young-Hoon Kim, Jong-Ki Kim, Byron Kim, Taek-Kyun Kim, Bo-Ra Kim, Dokyoon Kim, Min Chul Kim, Miso Kim, Seong-Min Kim, Jang Heub Kim, Hyeyoung Kim, Hyunwook Kim, Hee Su Kim, Young-Joo Kim, Reuben H Kim, Hong-Kook Kim, Soo Jung Kim, Sungryong Kim, Taejung Kim, Jung Soo Kim, Kyoung Hwan Kim, Sung Mok Kim, Daeeun Kim, Hyelim Kim, Beomsoo Kim, Ji-Woon Kim
To describe the phenotype of CLN-associated retinal dystrophy in a subset of patients at the Columbia University Medical Center, United States, and the Hospital das Clínicas de Pernambuco, Brazil, in Show more
To describe the phenotype of CLN-associated retinal dystrophy in a subset of patients at the Columbia University Medical Center, United States, and the Hospital das Clínicas de Pernambuco, Brazil, in comparison to the published literature. Eleven patients with confirmed biallelic variants in the CLN genes were evaluated via dilated fundus examination, clinical imaging, and full-field electroretinogram. A thorough literature search was conducted to determine previously published variants and associated phenotypes. Genetic testing confirmed the presence of variants in CLN3, CLN7/MFSD8, CLN8, and GRN/CLN11. Five novel variants were identified, and four novel phenotypes of previously published alleles were described. The phenotype differed among patients with variants in the same gene and sometimes among patients with the same allele. Substantial phenotypic variability among variants in the CLN genes makes identification of genotype-phenotype or allele-phenotype correlations challenging. Further study is required to establish an extensive database for adequate patient counseling. Show less
The glucocorticoid receptor (GR) is an important anti-cancer target in lymphoid cancers but has been understudied in solid tumors like lung cancer, although glucocorticoids are often given with chemot Show more
The glucocorticoid receptor (GR) is an important anti-cancer target in lymphoid cancers but has been understudied in solid tumors like lung cancer, although glucocorticoids are often given with chemotherapy regimens to mitigate side effects. Here, we identify a dexamethasone-GR mediated anti-cancer response in a subset of aggressive non-small cell lung cancers (NSCLCs) that harbor Serine/Threonine Kinase 11 (STK11/LKB1) mutations. High tumor expression of carbamoyl phosphate synthase 1 (CPS1) was strongly linked to the presence of LKB1 mutations, was the best predictor of NSCLC dexamethasone (DEX) sensitivity ( Show less
Cancer cell heterogeneity is a serious problem in the control of tumor progression because it can cause chemoresistance and metastasis. Heterogeneity can be generated by various mechanisms, including Show more
Cancer cell heterogeneity is a serious problem in the control of tumor progression because it can cause chemoresistance and metastasis. Heterogeneity can be generated by various mechanisms, including genetic evolution of cancer cells, cancer stem cells (CSCs), and niche heterogeneity. Because the genetic heterogeneity of CSCs has been poorly characterized, the genetic mutation status of CSCs was examined using Exome-Seq and RNA-Seq data of liver cancer. Here we show that different surface markers for liver cancer stem cells (LCSCs) showed a unique propensity for genetic mutations. Cluster of differentiation 133 (CD133)-positive cells showed frequent mutations in the Show less
Cultured human pluripotent stem cells (hPSCs) grow as colonies that require breakdown into small clumps for further propagation. Although cell death mechanism by single-cell dissociation of hPSCs has Show more
Cultured human pluripotent stem cells (hPSCs) grow as colonies that require breakdown into small clumps for further propagation. Although cell death mechanism by single-cell dissociation of hPSCs has been well defined, how hPSCs respond to the deadly stimulus and recover the original status remains unclear. Here we show that dissociation of hPSCs immediately activates ERK, which subsequently activates RSK and induces DUSP6, an ERK-specific phosphatase. Although the activation is transient, DUSP6 expression persists days after passaging. DUSP6 depletion using the CRISPR/Cas9 system reveals that DUSP6 suppresses the ERK activity over the long term. Elevated ERK activity by DUSP6 depletion increases both viability of hPSCs after single-cell dissociation and differentiation propensity towards mesoderm and endoderm lineages. These findings provide new insights into how hPSCs respond to dissociation in order to maintain pluripotency. Show less
Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide associatio Show more
Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide association study of lung adenocarcinoma of East Asian ancestry (21,658 cases and 150,676 controls; 54.5% never-smokers) and identified 12 novel susceptibility variants, bringing the total number to 28 at 25 independent loci. Transcriptome-wide association analyses together with colocalization studies using a Taiwanese lung expression quantitative trait loci dataset (n = 115) identified novel candidate genes, including FADS1 at 11q12 and ELF5 at 11p13. In a multi-ancestry meta-analysis of East Asian and European studies, four loci were identified at 2p11, 4q32, 16q23, and 18q12. At the same time, most of our findings in East Asian populations showed no evidence of association in European populations. In our studies drawn from East Asian populations, a polygenic risk score based on the 25 loci had a stronger association in never-smokers vs. individuals with a history of smoking (P Show less
A 10-year-old spayed female Pomeranian dog was referred for hepatic mass evaluation. Blood tests revealed mildly elevated alkaline phosphatase activities. Computed tomography revealed a mass with mult Show more
A 10-year-old spayed female Pomeranian dog was referred for hepatic mass evaluation. Blood tests revealed mildly elevated alkaline phosphatase activities. Computed tomography revealed a mass with multiple nodules on the right hepatic medial lobe adjacent to the caudal Show less
Over 90% of the U.S. adult population suffers from tooth structure loss due to caries. Most of the mineralized tooth structure is composed of dentin, a material produced and mineralized by ectomesench Show more
Over 90% of the U.S. adult population suffers from tooth structure loss due to caries. Most of the mineralized tooth structure is composed of dentin, a material produced and mineralized by ectomesenchyme derived cells known as odontoblasts. Clinicians, scientists, and the general public share the desire to regenerate this missing tooth structure. To bioengineer missing dentin, increased understanding of human tooth development is required. Here we interrogate at the single cell level the signaling interactions that guide human odontoblast and ameloblast development and which determine incisor or molar tooth germ type identity. During human odontoblast development, computational analysis predicts that early FGF and BMP activation followed by later HH signaling is crucial. Application of this sci-RNA-seq analysis generates a differentiation protocol to produce mature hiPSC derived odontoblasts Show less
Ovarian cancer is the leading cause of death among gynecologic cancers. Paclitaxel is used as a standard first-line therapeutic agent for ovarian cancer. However, chemotherapeutic resistance and high Show more
Ovarian cancer is the leading cause of death among gynecologic cancers. Paclitaxel is used as a standard first-line therapeutic agent for ovarian cancer. However, chemotherapeutic resistance and high recurrence rates are major obstacles to treating ovarian cancer. We have found that tephrosin, a natural rotenoid isoflavonoid, can resensitize paclitaxel-resistant ovarian cancer cells to paclitaxel. Cell viability, immunoblotting, and a flow cytometric analysis showed that a combination treatment made up of paclitaxel and tephrosin induced apoptotic death. Tephrosin inhibited the phosphorylation of AKT, STAT3, ERK, and p38 MAPK, all of which simultaneously play important roles in survival signaling pathways. Notably, tephrosin downregulated the phosphorylation of FGFR1 and its specific adapter protein FRS2, but it had no effect on the phosphorylation of the EGFR. Immunoblotting and a fluo-3 acetoxymethyl assay showed that tephrosin did not affect the expression or function of P-glycoprotein. Additionally, treatment with N-acetylcysteine did not restore cell cytotoxicity caused by a treatment combination made up of paclitaxel and tephrosin, showing that tephrosin did not affect the reactive oxygen species scavenging pathway. Interestingly, tephrosin reduced the expression of the anti-apoptotic factor XIAP. This study demonstrates that tephrosin is a potent antitumor agent that can be used in the treatment of paclitaxel-resistant ovarian cancer via the inhibition of the FGFR1 signaling pathway. Show less
Fetal bovine serum (FBS), which contains various nutrients, comprises 20% of the growth medium for cell-cultivated meat. However, ethical, cost, and scientific issues, necesitates identification of al Show more
Fetal bovine serum (FBS), which contains various nutrients, comprises 20% of the growth medium for cell-cultivated meat. However, ethical, cost, and scientific issues, necesitates identification of alternatives. In this study, we investigated commercially manufactured serum-free media capable of culturing Hanwoo satellite cells (HWSCs) to identify constituent proliferation enhancing factors. Six different serum-free media were selected, and the HWSC proliferation rates in these serum-free media were compared with that of control medium supplemented with 20% FBS. Among the six media, cell proliferation rates were higher only in StemFlex Show less
Although VEGF-B was discovered as a VEGF-A homolog a long time ago, the angiogenic effect of VEGF-B remains poorly understood with limited and diverse findings from different groups. Notwithstanding, Show more
Although VEGF-B was discovered as a VEGF-A homolog a long time ago, the angiogenic effect of VEGF-B remains poorly understood with limited and diverse findings from different groups. Notwithstanding, drugs that inhibit VEGF-B together with other VEGF family members are being used to treat patients with various neovascular diseases. It is therefore critical to have a better understanding of the angiogenic effect of VEGF-B and the underlying mechanisms. Using comprehensive in vitro and in vivo methods and models, we reveal here for the first time an unexpected and surprising function of VEGF-B as an endogenous inhibitor of angiogenesis by inhibiting the FGF2/FGFR1 pathway when the latter is abundantly expressed. Mechanistically, we unveil that VEGF-B binds to FGFR1, induces FGFR1/VEGFR1 complex formation, and suppresses FGF2-induced Erk activation, and inhibits FGF2-driven angiogenesis and tumor growth. Our work uncovers a previously unrecognized novel function of VEGF-B in tethering the FGF2/FGFR1 pathway. Given the anti-angiogenic nature of VEGF-B under conditions of high FGF2/FGFR1 levels, caution is warranted when modulating VEGF-B activity to treat neovascular diseases. Show less
Protein tyrosine kinase 7 (PTK7), a catalytically defective receptor tyrosine kinase (RTK), is often upregulated in various cancers. This study aimed to validate PTK7 as a target for breast cancer (BC Show more
Protein tyrosine kinase 7 (PTK7), a catalytically defective receptor tyrosine kinase (RTK), is often upregulated in various cancers. This study aimed to validate PTK7 as a target for breast cancer (BC) and investigate its oncogenic signaling mechanism. BC tissue analysis showed significantly elevated PTK7 mRNA levels, especially in refractory triple-negative breast cancer (TNBC) tissues, compared with normal controls. Similarly, BC cell lines exhibited increased PTK7 expression. Knockdown of PTK7 inhibited the proliferation of T-47D and MCF-7 hormone-receptor-positive BC cell-lines and of HCC1187, MDA-MB-231, MDA-MB-436, and MDA-MB-453 TNBC cells. PTK7 knockdown also inhibited the adhesion, migration, and invasion of MDA-MB-231, MDA-MB-436, and MDA-MB-453 cells, and reduced the phosphorylation levels of crucial oncogenic regulators including extracellular signal-regulated kinase (ERK), Akt, and focal adhesion kinase (FAK). Furthermore, PTK7 interacts with fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR) expressed in MDA-MB-231 cells. Knockdown of PTK7 decreased the growth-factor-induced phosphorylation of FGFR1 and EGFR in MDA-MB-231 cells, indicating its association with RTK activation. In conclusion, PTK7 plays a significant role in oncogenic signal transduction by enhancing FGFR1 and EGFR activation, influencing BC tumorigenesis and metastasis. Hence, PTK7 represents a potential candidate for targeted BC therapy, including TNBC. Show less
This study reports on diffuse leptomeningeal glioneuronal tumor (DL-GNT) in a 29-year-old male. DL-GNT is a rare central nervous system (CNS) tumor mostly seen in children and only few cases have been Show more
This study reports on diffuse leptomeningeal glioneuronal tumor (DL-GNT) in a 29-year-old male. DL-GNT is a rare central nervous system (CNS) tumor mostly seen in children and only few cases have been reported in adult patients. Our patient presented with a chronic headache that lasted for five months. MR imaging showed mild hydrocephalus, multiple rim-enhancing nodular lesions in the suprasellar cistern, diffuse leptomeningeal enhancement in the lumbosacral area, and multiple small non-enhancing cyst-appearing lesions not suppressed on fluid attenuated inversion recovery (FLAIR) images in the bilateral basal ganglia, thalami, and cerebral hemispheres. Under the impression of germ cell tumor with leptomeningeal seeding, the patient underwent trans-sphenoidal tumor removal. DL-GNT was pathologically confirmed and FGFR1 mutation was detected through a next-generation sequencing test. In conclusion, a combination of leptomeningeal enhancement and multiple parenchymal non-enhancing cyst-appearing lesions not suppressed on FLAIR images may be helpful for differential diagnosis despite overlapping imaging features with many other CNS diseases that have leptomeningeal enhancement. Show less
Aged skin is prone to viral infections, but the mechanisms responsible for this immunosenescent immune risk are unclear. We observed that aged murine and human skin expressed reduced levels of antivir Show more
Aged skin is prone to viral infections, but the mechanisms responsible for this immunosenescent immune risk are unclear. We observed that aged murine and human skin expressed reduced levels of antiviral proteins (AVPs) and circadian regulators, including Bmal1 and Clock. Bmal1 and Clock were found to control rhythmic AVP expression in skin, and such circadian control of AVPs was diminished by disruption of immune cell IL-27 signaling and deletion of Bmal1/Clock genes in mouse skin, as well as siRNA-mediated knockdown of CLOCK in human primary keratinocytes. We found that treatment with the circadian-enhancing agents nobiletin and SR8278 reduced infection of herpes simplex virus 1 in epidermal explants and human keratinocytes in a BMAL1/CLOCK-dependent manner. Circadian-enhancing treatment also reversed susceptibility of aging murine skin and human primary keratinocytes to viral infection. These findings reveal an evolutionarily conserved and age-sensitive circadian regulation of cutaneous antiviral immunity, underscoring circadian restoration as an antiviral strategy in aging populations. Show less
Allium cepa L. (A. cepa) is one of the oldest cultivated plants in the world. A. cepa has been used in traditional folk medicine to treat inflammatory disease in several regions, such as Palestine and Show more
Allium cepa L. (A. cepa) is one of the oldest cultivated plants in the world. A. cepa has been used in traditional folk medicine to treat inflammatory disease in several regions, such as Palestine and Serbia. A. cepa peel has a higher content of flavonoids, such as quercetin, than the edible parts. These flavonoids alleviate inflammatory diseases. However, the anti-inflammatory effects of A. cepa peel extract-obtained using various extraction methods-and their underlying mechanisms require further investigation. Although research to find safe anti-inflammatory substances in various natural products has been actively conducted for many years, it is important to continue identifying potential anti-inflammatory effects in natural materials. The purpose of this study was to investigate the ethnopharmacological properties of the A. cepa peel extract, whose efficacy when obtained through different extraction methods and underlying action mechanisms is not well known. The present study specifically aimed to observe the anti-inflammatory effects of the A. cepa peel extracts obtained using various extraction methods and the related detailed mechanisms of A. cepa peel extracts in lipopolysaccharide (LPS)-induced RAW264.7 cells. The total flavonoid content of the A. cepa peel extracts was determined the diethylene glycol colorimetric method and measured using a calibration curve prepared using quercetin as a standard solution. The antioxidant activity was evaluated using the ABTS assay, and cytotoxicity was measured using the MTT assay. NO production was measured using Griess reagent. Protein levels were measured by western blotting, and mRNA expression was measured by RT-qPCR. Secreted cytokines were analyzed using ELISA or cytokine arrays. In the GSE160086 dataset, we calculated Z-scores for individual genes of interest and displayed using a heat map. Of the three A. cepa peel extracts obtained using different extraction methods, the A. cepa peel 50% EtOH extract (AP50E) was the most effective at inhibiting LPS-induced nitric oxide (NO) and inducible nitric oxide synthase (iNOS). Furthermore, AP50E significantly reduced the levels of pro-inflammation cytokines interleukin (IL)-1α, IL-1β, IL-6, and IL-27. Additionally, AP50E directly inhibited the Janus kinase-signaling transducer and activator of transcription (JAK-STAT) pathway. These results showed that AP50E exhibited an anti-inflammatory effect in LPS-induced RAW264.7 mouse macrophages by directly inhibiting JAK-STAT signaling. Based on these findings, we propose AP50E as a potential candidate for the development of preventive or therapeutic agents against inflammatory diseases. Show less
Aged skin is prone to viral infections, but the mechanisms responsible for this immunosenescent immune risk are unclear. We observed that aged murine and human skin expressed reduced antiviral protein Show more
Aged skin is prone to viral infections, but the mechanisms responsible for this immunosenescent immune risk are unclear. We observed that aged murine and human skin expressed reduced antiviral proteins (AVPs) and circadian regulators including Bmal1 and Clock. Bmal1 and Clock were found to control rhythmic AVP expression in skin and such circadian-control of AVPs was diminished by disruption of immune cell interleukin 27 signaling and deletion of Bmal1/Clock genes in mouse skins, as well as siRNA-mediated knockdown of CLOCK in human primary keratinocytes. We found that treatment of circadian enhancing agents, nobiletin and SR8278, reduced infection of herpes simplex virus 1 (HSV1) in epidermal explants and human keratinocytes in a Bmal1/Clock-dependent manner. Circadian enhancing treatment also reversed susceptibility of aging murine skin and human primary keratinocytes to viral infection. These findings reveal an evolutionarily conserved and age-sensitive circadian regulation of cutaneous antiviral immunity, underscoring circadian restoration as an antiviral strategy in aging populations. Show less
IL-27 is an IL-12 family cytokine with immune regulatory properties, capable of modulating inflammatory responses, including autoimmunity. While extensive studies investigated the major target cells o Show more
IL-27 is an IL-12 family cytokine with immune regulatory properties, capable of modulating inflammatory responses, including autoimmunity. While extensive studies investigated the major target cells of IL-27 mediating its functions, the source of IL-27 especially during tissue specific autoimmune inflammation has not formally been examined. IL-27p28 subunit, also known as IL-30, was initially discovered as an IL-27-specific subunit, and it has thus been deemed as a surrogate marker to denote IL-27 expression. However, IL-30 can be secreted independently of Ebi3, a subunit that forms bioactive IL-27 with IL-30. Moreover, IL-30 itself may act as a negative regulator antagonizing IL-27. In this study, we exploited various cell type specific IL-30-deficient mouse models and examined the source of IL-30 in a T cell mediated autoimmune neuroinflammation. We found that IL-30 expressed by infiltrating and CNS resident APC subsets, infiltrating myeloid cells and microglia, is central in limiting the inflammation. However, dendritic cell-derived IL-30 was dispensable for the disease development. Unexpectedly, in cell type specific IL-30 deficient mice that develop severe EAE, IL-30 expression in the remaining wild-type APC subsets is disproportionately increased, suggesting that increased endogenous IL-30 production may be involved in the severe pathogenesis. In support, systemic recombinant IL-30 administration exacerbates EAE severity. Our results demonstrate that dysregulated endogenous IL-30 expression may interfere with immune regulatory functions of IL-27, promoting encephalitogenic inflammation in vivo. Show less
The absence of prominent, actionable genetic alternations in osteosarcomas (OS) implies that transcriptional and epigenetic mechanisms significantly contribute to the progression of this life-threaten Show more
The absence of prominent, actionable genetic alternations in osteosarcomas (OS) implies that transcriptional and epigenetic mechanisms significantly contribute to the progression of this life-threatening form of cancer. Therefore, the identification of potential transcriptional events that promote the survival of OS cells could be key in devising targeted therapeutic approaches for OS. We have previously shown that RUNX2 is a transcription factor (TF) essential for OS cell survival. Unfortunately, the transcriptional network or circuitry regulated by RUNX2 in OS cells is still largely unknown. The TFs that are in the RUNX2 transcriptional circuitry were identified by analyzing RNAseq and ChIPseq datasets of RUNX2. To evaluate the effect of SOX9 knockdown on the survival of osteosarcoma cells in vitro, we employed cleaved caspase-3 immunoblotting and propidium iodide staining techniques. The impact of SOX9 and JMJD1C depletion on OS tumor growth was examined in vivo using xenografts and immunohistochemistry. Downstream targets of SOX9 were identified and dissected using RNAseq, pathway analysis, and gene set enrichment analysis. Furthermore, the interactome of SOX9 was identified using BioID and validated by PLA. Our findings demonstrate that SOX9 is a critical TF that is induced by RUNX2. Both in vitro and in vivo experiments revealed that SOX9 plays a pivotal role in the survival of OS. RNAseq analysis revealed that SOX9 activates the transcription of MYC, a downstream target of RUNX2. Mechanistically, our results suggest a transcriptional network involving SOX9, RUNX2, and MYC, with SOX9 binding to RUNX2. Moreover, we discovered that JMJD1C, a chromatin factor, is a novel binding partner of SOX9, and depletion of JMJD1C impairs OS tumor growth. The findings of this study represent a significant advancement in our understanding of the transcriptional network present in OS cells, providing valuable insights that may contribute to the development of targeted therapies for OS. Show less
Obesity is a known risk factor for metabolic diseases and is often associated with chronic inflammation in adipose tissue. We previously identified the polyethoxylated flavonoid Nobiletin (NOB) as a c Show more
Obesity is a known risk factor for metabolic diseases and is often associated with chronic inflammation in adipose tissue. We previously identified the polyethoxylated flavonoid Nobiletin (NOB) as a circadian clock modulator that directly binds to and activates the ROR receptors in the core oscillator, markedly improving metabolic fitness in obese mice. Here, we show that NOB enhanced the oscillation of core clock genes in differentiated 3T3-L1 adipocytes, including ROR target genes such as Show less
KMT2A (11q23.3) gene rearrangements are found in acute leukemia and are associated with a poor or intermediate prognosis. MLLT10 is the fourth most common gene fusion partner for KMT2A. A reciprocal t Show more
KMT2A (11q23.3) gene rearrangements are found in acute leukemia and are associated with a poor or intermediate prognosis. MLLT10 is the fourth most common gene fusion partner for KMT2A. A reciprocal translocation t(10;11) is insufficient to produce an in-frame KMT2A/MLLT10 fusion, because the genes involved in the rearrangement have opposite transcriptional orientations. In order to bring KMT2A and MLLT10 into juxtaposition, complex rearrangements are required. Until now, conventional chromosome, fluorescence in situ hybridization (FISH), and reverse transcriptase-polymerase chain reaction (RT-PCR) studies have been used to detect KMT2A/MLLT10 fusions. However, conventional studies have limitations, such as poor and inconsistent resolution, when compared to next-generation sequencing (NGS). In this study, we report a pediatric patient with acute megakaryoblastic leukemia, in whom the cryptic KMT2A/MLLT10 fusion was not detected by KMT2A break-apart probe FISH and chromosome analysis, but detected by NGS. In this patient, NGS showed cryptic insertion of MLLT10 exons 9-24 into intron 9 of KMT2A, resulting in a KMT2A/MLLT10 fusion. Therefore, NGS is a valuable complementary option for the evaluation of structural aberrations, especially those with a cryptic size. Show less
Non-alcoholic fatty liver disease (NAFLD) associated with type 2 diabetes may more easily progress towards severe forms of non-alcoholic steatohepatitis (NASH) and cirrhosis. Although the Wnt effector Show more
Non-alcoholic fatty liver disease (NAFLD) associated with type 2 diabetes may more easily progress towards severe forms of non-alcoholic steatohepatitis (NASH) and cirrhosis. Although the Wnt effector transcription factor 7-like 2 (TCF7L2) is closely associated with type 2 diabetes risk, the role of TCF7L2 in NAFLD development remains unclear. Here, we investigated how changes in TCF7L2 expression in the liver affects hepatic lipid metabolism based on the major risk factors of NAFLD development. Tcf7l2 was selectively ablated in the liver of C57BL/6N mice by inducing the albumin (Alb) promoter to recombine Tcf7l2 alleles floxed at exon 5 (liver-specific Tcf7l2-knockout [KO] mice: Alb-Cre;Tcf7l2 Alb-Cre;Tcf7l2 In mice, loss of hepatic Tcf7l2 contributes to liver steatosis by inducing preferential metabolism of carbohydrates via DNL activation. Therefore, TCF7L2 could be a promising regulator of the NAFLD associated with high-carbohydrate diets and diabetes since TCF7L2 deficiency may lead to development of NAFLD by promoting utilisation of excess glucose pools through activating DNL. RNA-sequencing data have been deposited into the NCBI GEO under the accession number GSE162449 ( www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162449 ). Show less
Joo Hee Jeong, Yun Gi Kim, Suk-Kyu Oh+19 more · 2023 · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · Oxford University Press · added 2026-04-24
Idiopathic ventricular fibrillation (IVF) is a disease in which the cause of ventricular fibrillation cannot be identified despite comprehensive clinical evaluation. This study aimed to investigate th Show more
Idiopathic ventricular fibrillation (IVF) is a disease in which the cause of ventricular fibrillation cannot be identified despite comprehensive clinical evaluation. This study aimed to investigate the clinical yield and implications of genetic testing for IVF. This study was based on the multi-centre inherited arrhythmia syndrome registry in South Korea from 2014 to 2017. Next-generation sequencing-based genetic testing was performed that included 174 genes previously linked to cardiovascular disease. A total of 96 patients were clinically diagnosed with IVF. The mean age of the onset was 41.2 ± 12.7 years, and 79 patients were males (82.3%). Of these, 74 underwent genetic testing and four (5.4%) of the IVF probands had pathogenic or likely pathogenic variants (each having one of MYBPC3, MYH7, DSP, and TNNI3). All pathogenic or likely pathogenic variants were located in genes with definite evidence of a cardiomyopathy phenotype, either hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. Next-generation sequencing-based genetic testing identified pathogenic or likely pathogenic variants in 5.4% of patients initially diagnosed with IVF, suggesting that genetic testing with definite evidence genes of cardiomyopathy may enable molecular diagnosis in a minority of patients with IVF. Further clinical evaluation and follow-up of patients with IVF with positive genotypes are needed to unveil concealed phenotypes, such as the pre-clinical phase of cardiomyopathy. Show less
Atherogenesis is an insipidus but precipitating process leading to serious consequences of many cardiovascular diseases (CVD). Numerous genetic loci contributing to atherosclerosis have been identifie Show more
Atherogenesis is an insipidus but precipitating process leading to serious consequences of many cardiovascular diseases (CVD). Numerous genetic loci contributing to atherosclerosis have been identified in human genome-wide association studies, but these studies have limitations in the ability to control environmental factors and to decipher cause/effect relationships. To assess the power of hyperlipidemic Diversity Outbred (DO) mice in facilitating quantitative trait loci (QTL) analysis of complex traits, we generated a high-resolution genetic panel of atherosclerosis susceptible (DO-F1) mouse cohort by crossing 200 DO females with C57BL/6J males carrying two human genes: encoding apolipoprotein E3-Leiden and cholesterol ester transfer protein. We examined atherosclerotic traits including plasma lipids and glucose in the 235 female and 226 male progeny before and after 16 weeks of a high-fat/cholesterol diet, and aortic plaque size at 24 weeks. We also assessed the liver transcriptome using RNA-sequencing. Our QTL mapping for atherosclerotic traits identified one previously reported female-specific QTL on Chr10 with a narrower interval of 22.73 to 30.80 Mb, and one novel male-specific QTL at 31.89 to 40.25 Mb on Chr19. Liver transcription levels of several genes within each QTL were highly correlated with the atherogenic traits. A majority of these candidates have already known atherogenic potential in humans and/or mice, but integrative QTL, eQTL, and correlation analyses further pointed Ptprk as a major candidate of the Chr10 QTL, while Pten and Cyp2c67 of the Chr19 QTL in our DO-F1 cohort. Finally, through additional analyses of RNA-seq data we identified genetic regulation of hepatic transcription factors, including Nr1h3, contributes to atherogenesis in this cohort. Thus, an integrative approach using DO-F1 mice effectively validates the influence of genetic factors on atherosclerosis in DO mice and suggests an opportunity to discover therapeutics in the setting of hyperlipidemia. Show less
Breast cancer is a common tumor type among women, with a high fatality due to metastasis. Metastasis suppressors encode proteins that inhibit the metastatic cascade independent of the primary tumor gr Show more
Breast cancer is a common tumor type among women, with a high fatality due to metastasis. Metastasis suppressors encode proteins that inhibit the metastatic cascade independent of the primary tumor growth. Raf kinase inhibitory protein (RKIP) is one of the promising metastasis suppressor candidates. RKIP is reduced or lost in aggressive variants of different types of cancer. A few pre-clinical or clinical studies have capitalized on this protein as a possible therapeutic target. In this article, we employed two breast cancer cells to highlight the role of RKIP as an antimetastatic gene. One is the low metastatic MCF-7 with high RKIP expression, and the other is MDA-MB-231 highly metastatic cell with low RKIP expression. We used high-throughput data to explore how RKIP is lost in human tissues and its effect on cell mobility. Based on our previous work recapitulating the links between RKIP and SNAI, we experimentally manipulated RKIP in the cell models through its novel upstream NME1 and investigated the subsequent genotypic and phenotypic changes. We also demonstrated that RKIP explained the uneven migration abilities of the two cell types. Furthermore, we identified the regulatory circuit that might carry the effect of an existing drug, Epirubicin, on activating gene transcription. In conclusion, we propose and test a potential strategy to reverse the metastatic capability of breast cancer cells by chemically manipulating RKIP expression. Show less
Breast cancer is the most common cancer among women and the leading cause of cancer-related deaths worldwide. Despite various therapeutic strategies, its impact on the survival rate and quality of lif Show more
Breast cancer is the most common cancer among women and the leading cause of cancer-related deaths worldwide. Despite various therapeutic strategies, its impact on the survival rate and quality of life of patients remains limited. The Forkhead Box J3 (FOXJ3) transcription factor has been implicated in various cancers, including lung cancer, tongue squamous cell carcinoma, prostate cancer, and colorectal cancer. However, the role of FOXJ3 in breast cancer has not been elucidated. This study aimed to investigate the role of FOXJ3 in breast cancer development, migration, and invasion. FOXJ3 expression was analyzed in patient tissues and breast cancer cell lines. Loss-of-function and gain-of-function studies were performed using MDA-MB-231 and MCF7 cell lines, respectively. Cell proliferation, migration, and invasion assays were conducted, and the effects of FOXJ3 on Snail expression were examined. FOXJ3 is over-expressed in breast cancer tissues compared to normal counterparts and in various breast cancer cell lines. By modulating FOXJ3 expression in breast cancer cell lines, we observed its influence on cell proliferation, migration, and invasion. Microarray analysis and subsequent validation showed that FOXJ3 modulates Snail expression, a well-known transcription factor involved in epithelial-mesenchymal transition. FOXJ3 plays a role in cell proliferation, migration, and the regulation of Snail expression and may be a potential therapeutic target for breast cancer treatment. Show less
Canine lymphoma (CL) is one of the most common malignant tumors in dogs. The cause of CL remains unclear. Genetic mutations that have been suggested as possible causes of CL are not fully understood. Show more
Canine lymphoma (CL) is one of the most common malignant tumors in dogs. The cause of CL remains unclear. Genetic mutations that have been suggested as possible causes of CL are not fully understood. Whole-exome sequencing (WES) is a time- and cost-effective method for detecting genetic variants targeting only the protein-coding regions (exons) that are part of the entire genome region. A total of eight patients with B-cell lymphomas were recruited, and WES analysis was performed on whole blood and lymph node aspirate samples from each patient. A total of 17 somatic variants ( Show less